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Renal and systemic nitric oxide synthesis in rats with renal mass
reduction. In rats undergoing renal mass reduction (RMR) oral supple-
mentation with the nitric oxide (NO) precursor L-arginine increases
glomerular filtration rate and ameliorates signs of glomerular injury,
suggesting that chronic renal failure in the rats is a condition of low NO
formation in the kidney. On the contrary, data are available that in the
systemic circulation of uremics, both rats and human beings, NO is formed
in excessive amounts and may contribute to platelet dysfunction and
bleeding tendency, well-known complications of uremia. The present
study was designed to clarify the pathophysiology of renal and systemic
NO synthesis in uremia. We showed that renal er vivo NO generation,
measured as the conversion of [3H] L-arginine to [3H} L-citrulline, was
lower than normal in RMR rats, seven days after surgery, and progres-
sively worsened with time in close correlation with signs of renal injury.
Consistent with these results, urinary excretion of the stable NO metab-
olites, NO2 /N03, significantly decreased in rats with RMR. To go
deeper into the cellular origin and biochemical nature of this abnormality
we used two histochemical approaches that could locate either NO
synthase (NOS) catalytic activity (NADPH-diaphorase) or NOS isoen-
zyme expression (immunoperoxidase). NADPH-diaphorase documented
a progressive loss of renal NOS activity in RMR rats that co-localized with
a strong progressive decrease of inducible NOS isoenzyme (iNOS)
immunostaining. At variance with iNOS, endothelial cell NOS (ecNOS)
staining was rather comparable in RMR and control kidneys. At variance
to the kidney, in the systemic circulation of RMR rats the synthesis of NO
increased as reflected by higher than normal plasma NO2 7NO3 concen-
trations. High systemic NO likely derives from vessels as documented by
the increased NOS activity and higher expression of both iNOS and
ecNOS in the aorta of RMR rats. Up-regulation of systemic NO synthesis
might be an early defense mechanism against hypertension of uremia. On
the other hand, more NO available to circulating cells may sustain the
bleeding tendency, a well-known complication of uremia.
Nitric oxide (NO), an L-arginine derivative, is implicated in
neuronal transmission, immune response and vasodilation, beside
acting as a platelet function modulator [1, 2]. The conversion of
L-arginine to L-citrulline that leads to the formation of NO is
catalyzed by a family of NO synthase (NOS) enzymes that exist in
at least three distinct isoforms: neuronal NOS (nNOS), inducible
NOS (iNOS) and endothelial NOS (ecNOS). All three isoforms
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have been detected in the kidney [3, 4]. Immunohistochemical [5]
and reverse transcription-polymerase chain reaction (RT-PCR)
techniques [6] have located ecNOS in the glomerulus and afferent
and efferent arterioles. Immunohistochemistry [7, 8] and in situ
hybridization [8] show that the major Site of nNOS in the kidney
is the macula densa. Both isoforms are crucially involved in renal
pathophysiology and local release of NO serves to control renal
blood flow and modulates the activity of tubuloglomerular feed-
back [9—11]. The glomerular mesangium and afferent arteriole, as
well as various segments of the nephron, express the inducible
isoform of NOS (iNOS) [12—14], under basal conditions and after
immune activation [12, 13]. The steady state amount of iNOS
mRNA and protein in normal rat kidney is highest in tubuli of the
outer medulla, and in vitro studies on rat renal homogenates
showed that the specific activity of NO synthase in the medulla
was three times that in the cortex [15].
The renal vascular bed produces large amounts of NO whose
basal production maintains renal blood flow (RBF) and glomer-
ular filtration rate (GFR) [16, 17]. The kidney seems more
sensitive to acute inhibition of NO synthesis than other organs in
that the intravenous infusion of the NO synthesis inhibitor
NGnitroLargininemethyl ester (L-NAME), at a dose that did
not modify systemic blood pressure, reduced RBF and GFR in
normal rats [16].
Rats undergoing extensive renal mass reduction (RMR) de-
velop systemic hypertension and exhibit a decrease in both GFR
and RBF, despite an initial adaptive increase in single-nephron
GFR and plasma flow per nephron [18]. Animals with RMR also
develop severe proteinuria and structural changes in the kidney,
including glomerulosclerosis, which eventually lead to renal insuf-
ficiency [18, 19]. Reyes and coworkers observed that giving the
NO precursor L-arginine to RMR rats increased GFR and
effective renal plasma flow (ERPF), reduced proteinuria and
preserved renal morphology [20]. These findings were confirmed
by another study, which found that oral supplementation of
L-arginine at a much lower dose had a protective effect on urinary
protein excretion and renal function in RMR rats [21]. It thus
appears that chronic renal failure in the rats is a condition of low
NO formation in the kidney and that exogenous correction of the
defect markedly limits disease progression.
On the contrary, data are available that in the systemic circu-
lation of uremics, either in experimental animals or humans, NO
is formed in excessive amounts. Therefore, rats with RMR
[22]—like human beings [23]— have a prolonged bleeding time that
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returns completely to normal when the animals are given N-
monomethyl-L-arginine (L-NMMA), a competitive inhibitor of
NO synthase [24]. In a recent study [25] plasma from ñremic
patients induced NO synthesis in cultured endothelial cells much
more than plasma from healthy subjects.
The present study was designed to clarify the pathophysiology
of NO synthesis in uremia and was aimed at unraveling the
apparent conflict of less NO being formed in the kidney in the face
of enhanced systemic availability.
METHODS
Chemicals
[3H] L-arginine (56.4 Ci/mmol) was purchased from New
England Nuclear, (Boston, MA, USA). Tumor necrosis factor a
(TNFa, specific activity 6.1 >< i07 U/mg) and interleukin 1 13
(IL-113, specific activity 5 X io U/mg) were a gift from BASF
KNOLL (Ludwigshafen, Germany); interferon y (INFy) was
obtained from Institut Roussel Uclaf (Paris, France). Dowex AG
50 WX-8 was from Bio Rad (Richmond, CA, USA). N-2-hydroxy-
ethylpiperazine-N'-2-ethanesulfonic acid (HEPES) and diamino-
benzidine tablets were from Merck (Darmstadt, Germany), N-
nitro-L-arginine, /3-NADPH, nitroblue tetrazolium, Triton X-100,
diphenyliodonium (DPI) and all other chemicals were from Sigma
Chemicals (St. Louis, MO, USA). A low-nitrate diet was prepared
from commercial standard diet (Rieper, Bolzano, Italy) by water
nitrate extraction. Briefly, the pulverized diet was resuspended in
distilled water at 37°C and whipped, then was filtered and dried
up. Since water-soluble vitamins and minerals were lost by water
extraction, the low-nitrate diet was supplemented with minerals,
vitamins, choline, DL-methionine, L-arginine, in amounts recom-
mended by the American Institute of Nutrition.
Experimental design
Male Sprague-Dawley rats (Charles River Italia, Calco, Italy;
N = 37) underwent right nephrectomy and ligation of two or three
branches of the left renal artexy according to Olson et al [26].
Thirty-seven rats were sham-operated and served as controls
(CTR). Procedures involving animals and their care were con-
ducted in conformity with the institutional guidelines that are in
compliance with national and international laws and policies
(EEC Council Directive 86/609, OiL 358, Dec 1987; NIH Guide
for the Care and Use of Laboratory Animals, NIH Publ. No.
85-23, 1985).
To evaluate renal NO synthesis three groups of RMR rats and
three groups of control rats were studied at seven days (N = 5), 30
days (N = 6) and 90 days (N = 6) after surgery. Animals were
sacrificed by ether anesthesia, the kidneys were removed and
decapsulated. A specimen of renal tissue was embedded in
paraffin for evaluation of glomerulosclerosis and tubulointerstitial
damage, and the remaining tissue was minced into a fine paste and
homogenized by sieving (stainless steel sieve, 140 mesh; Giuliani,
Turin, Italy) to obtain a total renal tissue preparation consisting of
a mixture of glomeruli, tubuli and single cells.
Portions of renal tissue (about 1.5 mg protein) from control and
RMR rats were incubated in Hank's buffer (Tris 27.5 mmol/liter,
Na2HPO4 0.7 mmol/liter, KH2PO4 0.74 mmol/liter, KC1 5.4
mmol/liter, NaC1 136 mmol/liter, dextrose 9.6 mmol/liter, CaCI2
1.87 mmol/liter and MgSO4 0.8 mmol/liter) supplemented with
L-arginine (10 jxmol/liter) and [3H] L-arginine (0.5 jxCi) for eight
hours at 37°C in a water bath under slow shaking. Renal NO
synthesis was evaluated by measuring the conversion of [3H]
L-arginine to [3H] L-citrulline and the data were corrected for the
protein content of each sample.
Portions of Hank's buffer containing [3H] L-arginine were also
incubated for eight hours and used as blanks. To verify whether
[3H} L-citrulline production actually reflected NO synthase activ-
ity, samples of renal tissue from control rats (N = 3) were
incubated for eight hours with both [3H] L-arginine and Nu-nitro-
L-arginine (L-NNA, 300 ,itmol/liter), a specific inhibitor of NO
synthesis. As positive controls, portions of control renal tissue
(N = 3) were incubated with a cocktail of cytokines (TNFa 1000
U/mi, IL-113 10 U/mI, INFy 200 U/mI) for 24 hours in the presence
of [3H] L-arginine and excess L-arginine (100 xmol/liter) [27].
To obtain an indirect in vivo index of renal NO synthesis,
24-hour urinary excretion of nitrites/nitrates (N02/N03), the
stable NO metabolites, was measured in additional control (N =
8) and RMR rats (N = 8) studied longitudinally 7, 30 and 90 days
after the surgical procedure. For each time point, to minimize
dietary N03 intake, rats were fed a low N03 diet (< 8 nmol/g)
and given distilled water to drink, starting three days before the
24-hour urine collection [28]. Metabolic cages were cleaned with
a germicidal soap to prevent N02 and N03 formation by
bacteria [28]. At the same time points plasma samples were
collected from RMR and CTR rats to measure plasma NO2 /
NO3 — concentrations as an indicator of systemic NO synthesis. At
90 days animals were sacrificed and portion of renal tissue was
paraffin-embedded for histological evaluation.
To evaluate any differences in activity and localization of renal
and systemic NO synthase isoenzymes in RMR and CTR rats,
three additional groups of RMR and CTR rats (N =4 for each
group) were sacrificed at 7, 30 and 90 days after surgery. The
catalytic activity of NOS in the kidney and thoracic aorta was
assessed by isoenzyme-independent enzymatic oxidation of ni-
troblue tetrazolium in the presence of NADPH (NADPH-diaph-
orase). Expression of the endothelial (ecNOS) and inducible
(iNOS) isoforms of NO synthase was evaluated on the same
tissues by immunoperoxidase with specific antibodies. A portion
of tissue was paraffin-embedded for histological evaluation.
Renal function, measured as serum creatinine, urinary protein
excretion and bleeding time were assayed in all RMR and CTR
rats.
Determination of [3H1 L-citrulline formation from [3H1
L-arginine
Incubations were stopped by adding one volume of ice-cold
15% trichloroacetic acid (TCA). TCA-treated samples were cen-
trifuged at 10,000 X g to precipitate proteins. The supernatant
was extracted five times with one volume of water-saturated ether,
vacuum lyophilized and resuspended in 2 ml HEPES, pH 5.5, and
applied to 2 ml wet bed volumes of Dowex AG 50 WX-8 (100 to
200 mesh, Li form), followed by 2 ml of water. [3H] L-citrulline
was quantitated by liquid scintillation counting in the 4-mi column
effluent and identified as described [29].
Urinary and plasma nitrites/nitrates
NO2/N03 were measured semi-automatically using a High
Performance Liquid Chromatograph (model 421A; Beckman
Instruments Inc., Berkeley, CA, USA) coupled with a 163 Vari-
able Wavelength detector (Beckman Instruments Inc.) and a
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Shimadzu C-R3A Chromatopac Recorder-Integrator (Kjoto, Ja-
pan). Briefly, urine and plasma samples were treated with zinc
sulfate (60 gmol/liter, final concentration) and centrifuged to
eliminate proteins. Supernatants were eluted into a Dowex AG 50
WX-8 column followed by a cadmium column which catalyzes the
reduction of nitrate to nitrite (eluent borate buffer, pH = 8.5).
The post-column eluate reacted with Griess reagent [5% H3P04,
1% sulphanylic acid, 0.1% of N-(1-naphthyl)-ethylenediamine,
vol:vol:vol] to form a purple azo dye, and the color was analyzed
with a UV-VIS detector at A = 504nm. The absorbance peak area
was measured and the NO2 /NO concentration in the sample
was calculated by extrapolation from a standard nitrate curve.
Values were corrected for recovery which averaged 80% as
determined by addition of known amounts of standard nitrate to
an additional portion of each sample [30].
Tissue preparation for histochemistry
Animals were anesthetized by diethyl ether inhalation; left
kidneys were perfused through the descending aorta for five
minutes with PBS to wash out the blood, then for 10 minutes with
4% p-formaldehyde in PBS. Biopsy slices 2 mm thick were cut
perpendicularly to the major axis of the kidney and fixation was
completed by immersion in p-formaldehyde solution overnight.
The thoracic aorta was surgically dissected and fixed by immersion
in 4% p-formaldehyde in PBS overnight at 4°C. A portion of each
sample was processed for conventional paraffin inclusion, and the
remainder was treated with 10% sucrose in PBS for cryoprotec-
tion, then frozen in liquid nitrogen.
NADPH-diaphorase
Frozen sections 3 m thick were cut on a cryostat (HM500-O;
Microm, Zeiss Oberkochen, Germany). Sections were air-dried,
then washed in PBS 0.05 M pH 7.4 for five minutes at room
temperature and permeabilized by immersion in 0.3% Triton
X-100/PBS 0.01 M, pH 7.2 at 4°C for 30 minutes [31]. NADPH-
diaphorase reaction was performed by incubating slides with 1 mrvi
I3NADPH/0.2 mrvi nitroblue tetrazolium/100 mM Tris-HC1 buffer
pH 8.0 containing 0.2% Triton X-100 for one hour at 37°C [32].
The reaction was stopped by rinsing sections in PBS 0.05 M pH 7.4.
In all experiments the reproducibility of the reaction was
followed on a control tissue section. Negative controls were run
without NADPH or in the presence of the NO synthesis inhibitor
DPI [15, 331; reactivity was totally NADPH-dependent and was
abolished by DPI.
Slides were observed on a DM/RB microscope (Leitz, Leica,
Milan, Italy) by a pathologist blind to the nature of the experi-
ment.
Immunoperoxidase
Three-fiLm paraffin sections from renal and aortic tissue were
processed for light microscopy immunohistochemistry using an
avidin-biotin horseradish peroxidase complex technique (ABC
method, ABC-Elite; Vector Laboratories, Burlingamc, CA, USA).
Rabbit polyclonal antibody directed against mouse macrophage
inducible NOS (Transduction Laboratories, Exeter, UK) and
mouse monoclonal antibody against human endothelial NOS
(Transduction Laboratories) were used. Both antibodies recog-
nize rat NOS antigens [34, and Transduction Laboratories cata-
log]. Briefly, the sections were dewaxed, rehydrated and incubated
for one hour with 0.3% H202 in methanol to quench endogenous
peroxidase. Tissue was permeahilized in 0.1% Triton X-100 in
PBS 0.01 M, pH 7.2, for 30 minutes and aspecificities were blocked
by 30 minutes incubation with non-immune sera (goat serum for
anti-iNOS, horse serum for anti-ecNOS). All the above steps were
carried out at room temperature. Slides were then incubated
overnight at 4°C in a moist chamber with the primary antibody
(anti-iNOS 1:25, anti-ecNOS 1:150) in PBS/1% bovine serum
albumin (Miles, Bayer, Milan, Italy), followed by the secondary
antibody (biotinylated goat-anti-rabbit IgG, or biotinylated horse-
anti-mouse IgG), ABC solution, and finally developed with diami-
nobenzidine as described. The sections were then counterstained
with Harris hematoxylin (Biooptica, Milan, Italy). Negative con-
trols were obtained by omitting the primary antibody on a second
section present on all the slides.
For the detection of ecNOS on renal tissue, as the above
method did not clearly separate any signal from the background
(data not shown), an amplification system was employed. The
sections were processed as described above, but before the ABC
solution they were incubated with a monoclonal antibody anti-
biotin (dilution 1:30; DAKO, Milan, Italy) for 30 minutes at room
temperature, followed by another incubation with biotinylated
antibody. Methyl green was employed to counterstain the samples
instead of hematoxylin.
The slides were observed under the light microscope.
Histology
For morphological evaluations 3-xm thick sections were cut
from the paraffin blocks and stained with Masson's Trichrome and
PAS. Glomerulosclerosis was semiquantitatively analyzed by light
microscopy by the same pathologist who did the immunohisto-
chemistry examinations. Briefly, 0 was attributed to normal gb-
meruli, 1+ to glomeruli with sclerosis 0 to 30%, 2+ to glomeruli
with 30% to 60%, 3+ to gbomeruli with 60% to 100%, and 4+ to
completely sclerosed tufts. The numbers of glomeruli for each
class were counted and the sclerosis score was calculated as a
balanced average [35]. Tubulointerstitial damage and tubular
casts were also evaluated [36].
Analytical
Serum creatinine was measured with the alkaline picrate
method [371. Urinary protein concentration was determined by
the Coomassie blue G dye-binding assay with BSA as standard
[37]. Protein content of renal tissue samples was measured with
the method of Lowry et al [38]. Bleeding time was determined as
previously described [24].
Statistical analysis
All results are expressed as mean Sn. Data on NO production
in renal tissue incubated with L-NNA or the cocktail of cytokines
were analyzed by Student's I-test for unpaired data. Renal NO
synthesis, proteinuria, serum creatinine concentration and bleed-
ing time in control and RMR rats 7, 30 and 90 days after surgery
were analyzed by the Kruskal-Wallis test. Data on plasma and
urinary nitrites/nitrates were analyzed by between-within analysis
of variance. Linear regression analysis was used to correlate NO
synthesis with the degrees of proteinuria and glomeruloscierosis
in RMR rats, and the Spearman correlation test was used to
correlate renal NO synthesis with tubular damage. Statistical
significance was defined as P < 0.05.
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Table 1. Laboratoiy findings in RMR and CTR rats
Group Day
Urinary proteinc
mg/day
Serum creatininec
mg/dl
Glomeruli with
sclerotic changes'
% (range)
Tubular
damaged
Interstitial
infiltrated Casts"
Bleeding timea
seconds
RMR
RMR
RMR
7
30
90
47 3C
275 335
292 40a
0.97 0.07
1.5 0.06'
1.7 0.08at
4(0—13)
28(0—71)
39(8—66)
+/—
++
++/+++
—
+/++
++
+1—
+
+
187 5.42a
201 l1.7
281 12.7a
CTR 7 22 0.6 0.61 0.01 0 — — — 95 3.45
CTR 30 30 1.1 0.62 0.01 0 — — 111 1.71
CTR 90 24 2.1 0.70 0.01 0 — — — 93 2.35
Data are mean SE.
aP < 0.01 vs. CTR at corresponding time
"P < 0.05 vs. RMR at day 7
C N = 37 (7 days after surgery), N = 28 (30 days after surgery), N = 18 (90 days after surgery), see experimental designd N = 9 (7 days after surgery), N = 10 (30 days after surgery), N = 18 (90 days after surgery), see experimental design
RESULTS
In RMR rats urinary protein excretion was significantly higher
than in control rats at each time point considered (Table 1).
Proteinuria was already present seven days after surgery (P <
0.01) and further increased on days 30 and 90 (P < 0.01). During
time rats with RMR developed progressive renal insufficiency as
documented by serum creatinine values (Table 1). RMR rats
sacrificed seven days after surgery as well as all CTR rats had no
renal lesions. In RMR rats 28% and 39% of glomeruli respectively
had sclerotic lesions on days 30 and 90. At the same times in RMR
rats abnormalities also affected non-glomerular structures and
included tubular atrophy, casts in the distal tubuli, interstitial
inflammation and fibrosis (Table 1).
Seven days after renal ablation bleeding time values were
significantly (P < 0.01) longer than in controls. By 30 and 90 days
hemostatic changes were even more evident (Table 1).
NO synthesis in renal tissue from CTR and RMR rats
Normal renal tissue synthesized considerable amounts of NO in
vitro as indicated by the conversion of [3HJ L-arginine to [3HJ
L-citrulline. Generation of [3Hj L-citrulline in CTR renal tissue
was almost completely abolished (1.77 0.31 vs. 20.31 1.65
pmol/mg protein, N = 3, P < 0.05 vs. vehicle) by the addition of
300 ,u.mol/liter L-NNA, a specific NO synthesis inhibitor, indicat-
ing that [3H] L-citrulline formation closely reflected renal NO
synthesis. When normal renal tissue was preincubated with cyto-
kines in the presence of excess L-arginine, NO synthesis was
significantly (P < 0.05) increased (17.24 1.48 nmol/mg protein,
N = 3) compared to unstimulated tissue (7.31 0.89 nmol/mg
protein, N = 3), indicating the presence of inducible NO synthase
enzyme.
As shown in Figure 1, NO release was significantly lower in
renal tissue from RMR rats than control rats at each time point (7
days, 14.09 2.85 vs. 22.43 0.72, N = 5, P < 0.05; 30 days,
8.82 1.24 vs. 17.19 2.49, N = 6, P < 0.05; 90 days, 0.61 0.25
vs. 17.33 3.16, N = 6,P < 0.01; pmol/mg protein). In RMR rats
renal NO synthesis paralleled renal disease progression and was
almost undetectable 90 days after the surgical procedure (P <
0.01 vs. 7 days and 30 days). Renal NO synthesis negatively
correlated with the degree of proteinuria (r = 0.50, N = 17, P <
0.05) as well as with glomeruloscierosis (r = 0.72, N = 17, P <
0.05) or tubular damage (rho = 0.76, N = 17, P < 0.05).
Consistently with ex-vivo data, urinary N02/N03 excretion
was significantly lower in RMR rats than in control rats through-
Time, days
Fig. 1. Production of NO by renal tissue from RMR rats (•) seven days
(N 5), 30 days (N = 6) and 90 days (N = 6) after the surgical procedure,
compared to age-matched sham-operated rats (CTR rats; LI). Data are
mean SE. P < 0.05, 0.01 versus control rats, °P < 0.01 versus
RMR 90 days.
out the experimental period (7 days, 822 242 vs. 6155 1531,
P < 0.05; 30 days, 566 369 vs. 4653 1033, P < 0.01; 90 days,
479 180 vs. 3211 569, P < 0.01; nmol/24 hr, N = 8; Fig. 2).
In CTR rats studied seven days after surgery, urinary N02/N03
excretion was numerically but not significantly higher than at 30
and 90 days. Urinary excretion of NO2/NO3 in normal rats of
comparable age was 3750 765 nmol/24 hr (N = 4), suggesting
that the higher urinary NO2 /NO3 . in CTR animals seven days
after surgery might be related to the sham operation.
Location of NOS activity and NOS isoeuzymes in CTR and
RMR kidney
NADPH-diaphorase. In order to locate renal NO synthesis at
cellular level we used the NADPH-diaphorase technique, which
detects catalytic NOS activity irrespective of the enzyme isoform.
NADPH-diaphorase staining in CTR rats was similar at all time
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points examined after sham operation, except for a slightly higher
intensity seven days after surgery (Fig. 3 A-C). Staining was
stronger in the macula densa [3, 5, 8], while the glomerular tuft
showed a weak positivity that seemed to draw the capillary
network [10]. The cytoplasm of most cortical and outer medullary
tubuli was intensely colored while the inner medulla was almost
negative [15]. The vessels showed marked endothelial staining and
frequently the arterial smooth muscle cells presented a well
detectable signal too (Fig. 3 A-C) [3]. This pattern was compara-
ble to that recently observed by McKee, Scavone and Nathanson
in the human kidney [15].
Renal sections from RMR rats seven days after the surgical
procedure showed the same staining distribution as in CTR rats,
but a weaker intensity (Fig. 3D). After that the diaphorase
staining pattern changed strikingly in RMR rats. By 30 days the
decrease in NOS activity was focal and affected some portions in
the cortex and outer medulla more than others. Areas of de-
creased staining frequently corresponded to areas of sclerosis
where no signal could be found anywhere in tubuli and glomeruli.
An exception was the macula densa where staining was substan-
tially preserved compared to CTRs. The diaphorase signal was
also detected in most interstitial capillaries and afferent and
efferent arterioles (Fig. 3E).
At 90 days there was a further diffuse decrease in NOS activity,
NADPH-diaphorase staining being barely detectable in most
tubuli and glomeruli. Some areas along the vascular endothelium
of interstitial vessels and afferent/efferent glomerular arterioles
stained positively but weakly (Fig. 3F). In the rare morphologi-
cally preserved regions, low NADPH diaphorase activity was still
present in glomeruli.
iNOS and ecNOS immunoperoxidase. Expression of the induc-
ible isoform of NOS was similar in all control groups. The enzyme
showed focal staining in a few glomerular cells in the tuft as well
as in the epithelium of the Bowman capsule. In the cortex,
staining was intense on collecting ducts as well as on few proximal
tubuli, while most distal tubuli had a weak signal (Fig. 4B). Outer
medullary tubuli stained strongly, while vessels, interstitial areas
and inner medullary tubuli, except thick ascending limbs, were
completely negative (data not shown).
RMR kidney sections presented a progressive decrease of iNOS
antigen compared to CTR kidneys. Thus, at seven days iNOS
staining had the same distribution as controls, though it was
weaker. Like the diaphorase staining, 30 days after surgery iNOS
immunoreactivity had markedly decreased in glomeruli as well as
in most tubuli, particularly in areas affected by fibrosis. By 90 days
the iNOS signal dropped further in glomeruli and tubuli with no
sclerotic lesions, and no iNOS immunoreactivity at all was detect-
able in sclerotic regions (Fig. 4C).
In CTR rats a low but specific ecNOS signal was localized in
glomerular capillary loops [5], particularly in the glomerular
endothelium, and in the brush border of proximal tubuli (Fig. 5A).
Staining was strong in the endothelium of the interlobular arter-
ies, interstitial arterioles and capillaries [39]. In contrast to iNOS,
ecNOS staining was rather comparable in RMR and control
kidneys. However, in RMR rats the ecNOS signal was reduced in
glomeruli affected by sclerosis, possibly because of loss of func-
tional endothelium (Fig. SC).
Omitting the primary antibody, against either iNOS or ecNOS
did not produce any staining of adjacent sections in all experi-
ments (Fig. 4A and Fig. 5 B, D).
Systemic NO synthetic pathway in CTR and RMR rats
Plasma N02JN03 concentrations are given in Figure 6. In
CTR animals, plasma N02/NO3 did not change with time (7
days, 23.88 5.61; 30 days, 18.14 2.30; 90 days, 20.37 4.60;
nmol/ml, N = 8). By contrast, in RMR rats plasma N021N03
gradually rose (7 days, 35.42 4.70; 30 days, 34.25 6.92; 90
days, 43.82 8.51; nmol/ml, N = 8), to such a degree that at 90
days absolute values were significantly different from those in the
corresponding CTR animals (P < 0.05, Fig. 6).
Thoracic aorta from CTR rats stained weakly for NADPH-
diaphorase on endothelial cells with a few traces on the vessel wall
(Fig. 7A) [40]. Endothelial staining appeared to be more intense
in aorta sections from RMR on day 7 than in CTR rats and further
increased at 30 and 90 days, suggesting higher NOS activity.
Furthermore, at the latter time point a segmentary marked
increase in the diaphorase signal was observed also in smooth
muscle cells of RMR aortas, compared to CTR aortas (Fig. 7B).
In CTR rats immunoperoxidase showed a strong ecNOS signal
on the aortic endothelium (Fig. 7C) [39], whereas iNOS was found
on smooth muscle cells of arterial wall and on the endothelium
(Fig. 7E). Of note, endothelial iNOS staining was weaker than
ecNOS.
In line with the diaphorase results, ecNOS expression in RMR
aortas was greater than in cTRs and increased with time (Fig.
7D). As for iNOS, there were no appreciable differences between
CTR and RMR aortas at 7 and 30 days. By 90 days a sharp
increase in the iNOS signal was observed in RMR aortas, in both
endothelial and smooth muscle cells (Fig. 7F).
When the primary antibodies was omitted no staining was
observed in adjacent sections in all experiments (Fig. 7 G, H).
DISCUSSION
In the present report we have shown that in rats with RMR
renal generation of NO was remarkably lower than normal. The
abnormality was already evident seven days after surgery and
progressively worsened with time, in close correlation with signs of
7 30 90
Time, days
Fig. 2. Urinary excretion of nitrites/nitrates in (U) RMR rats seven days(N = 8),30 days (N = 8) and 90 days (N = 8) after the surgical procedure,
compared to age-matched sham-operated rats (CTR rats; El). Data are
mean SE. < 0.05, P < 0.01 versus control rats.
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renal injury. Consistent with these results, N02/N03 urinary that progressive nephropathies were associated with a reduced
excretion significantly decreased in rats with RMR compared to capacity of the kidney to generate NO.
control animals. These data support previous reports [20, 21, 411 To go deeper into the cellular basis and the biochemical nature
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Fig. 5. ecNOS immunoperoxidase staining of CTR (A) and RMR (C) rats studied 90 days after surgery. Specific reactivity is present on glomerular
capillary ioops both in CTR and in RMR rats (methyl green counterstaining). No staining is seen when the primary antibody is omitted both in CTR
(B) and in RMR (D) kidneys (magnification X355, bar = 35 jim).
Fig. 3. NADPH-diaphorase staining of kidney cortex. Reactivity is strong
on the macula densa and tuhuli in CTR kidney (A, B, C: CTR rats studied
7, 30 and 90 days after surgery; D, E, F: RMR rats studied 7, 30 and 90
days after surgery). Seven days after surgery in RMR rats (D) staining is
weaker. E. NADPH-diaphorase staining in kidney cortex of RMR rats
studied at 30 days shows one glomerulus and a few normal tubuli
surrounding a negative area. A similar negative area is shown in panel F
(RMR rats on 90 days), where only the afferent and efferent arterioles of
a sclerosed glomerulus and few tubuli are stained (magnification X90;
bar = 80 jim). Publication of this figure in color was made possible by a
grant from Hoechst Marion Roussel, Frankfurt am Main, Germany.
Fig. 4. iNOS immunoperoxidase staining of CTR (B) and RMR (C) 90
days after surgery. Note the groups of tubuli strongly marked, and the
focal glomerular staining in CTR rats as compared to the diffuse iNOS
decrease in RMR (Harris hematoxylin counterstaining). A. No staining is
seen with omission of the primary antibody (magnification >< 180; bar = 40
jim). Publication of this figure in color was made possible by a grant from
Hoechst Marion Roussel, Frankfurt am Main, Germany.
Time, days
Fig. 6. Plasma concentration of nitrites/nitrates in RMR rats () seven
days (N = 8), 30 days (N = 8) and 90 days (N = 8) after surgery,
compared to age-matched sham-operated rats (CTR rats, fl). Data are
mean SE. *P < 0.05 versus control rats.
of this abnormality, we used two histochemical approaches, that
could locate either NOS catalytic activity [5, 7, 15] or NOS
isoenzyme expression [5, 7, 15, 39]. NADPH-diaphorase docu-
mented a progressive loss of renal NOS activity in RMR rats in all
the structures examined including glomeruli (except macula densa
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and afferent and efferent arterioles), proximal tubules and collect
ing ducts. A strong, progressive decrease of iNOS immunostaining
was also observed, colocalizing with the loss of NADPH-diapho-
rase signal.
In glomeruli soon after surgical ablation of renal mass inflam-
matory mediators such as platelet-derived growth factor (PDGF)
[42] and transforming growth factor /3 (TGF/3) [43] are formed in
excessive amounts. PDGF and TGFJ3 are both potent inhibitors of
NO synthesis and dose-dependently block IL-l/3-induced iNOS
mRNA in rat mesangial cells [44, 45]. It is therefore conceivable
that an exaggerated concentration of PDGF and TGFI3 in gb-
meruli of rats with RMR down-regulates glomerular iNOS. The
recent observation that the potent vasoconstrictor and promito-
genic peptide endothelin-1 (ET-l) inhibits IL-113-stimulated tran-
scription of iNOS [46] offers one possible explanation for the
reduced expression of iNOS in the outer medulla of rats with
RMR. Renal ET-1 gene expression and synthesis time-depen-
dently increased in the RMR model and correlated with the
progressive renal injury [47, 37]. Although the cellular origin of
the increased renal synthesis of ET-1 is not yet clear, preliminary
in situ hybridization studies in our laboratory in RMR rats [48]
showed intense staining for ET-1 mRNA, mainly in the proximal
tubular cells. One may speculate that in rats with RMR excessive
ET-1 formed by the proximal tubular epithelium down-regulates
iNOS in the outer medulla.
Unlike iNOS, the isoenzyme ecNOS is expressed in comparable
amounts in RMR and control kidneys. This is not surprising, since
PDGF and TGF/3 do not affect ecNOS [2, 49 while ET-1 even
stimulates it [50].
NO in the renal vasculature and macula densa appears to
control renal blood flow and tubulo-glomerular feedback [9, 10,
51]. Deng and Baylis [52] found that chronic administration of a
NO synthesis inhibitor to rats increased systemic and glomerular
blood pressure, followed by glomerular damage. These data
suggest that reduced renal NO synthetic capacity may contribute
to starting or maintaining intraglomerular hypertension.
Besides its vasodilatoxy properhes, NO inhibits mesangial cell
proliferation [53] and extracellular matrix synthesis [54, 55]. Thus,
dietary supplementation with L-arginine to rats with RMR limited
the early phase of cell proliferation in the remnant glomerulus
[56].
It has been proposed that NO production by iNOS in medullary
thick ascending limbs serves to maintain and regulate medullaiy
blood flow and oxygenation [57]. There is also evidence that NO,
through the generation of cGMP, inhibits renal tubular Na,K-
ATPase [58], resulting in diuresis and natriuresis [58, 59]. This
mechanism could at least partly explain the antidiuretic and
antinatriuretic actions of low doses of NOS inhibitors in the
absence of any measurable effect on either RBF or GFR [60]. It
is tempting to speculate that a decrease in tubular NO synthesis in
RMR rats may cause salt retention and aggravate glomerular and
systemic hypertension. This is supported by a recent report that a
high salt diet exacerbated the blood pressure elevation and
worsened both glomeruloscierosis and interstitial fibrosis in RMR
rats [61].
Diminished renal NO formation could therefore play some role
in the hemodynamic and non-hemodynamic abnormalities re-
ported in the model of extreme renal ablation [18] that precede
and eventually lead to the development of glomeruloscierosis and
renal scarring. Present findings of a linear inverse correlation
between the amount of NO formed by renal tissue and indexes of
renal damage in rats with remnant kidney are consistent with this
interpretation. Also relevant is the fact that administration of
L-arginine to rats with subtotal nephrectomy limits renal disease
progression, as reflected by less proteinuria and less structural
damage [20]. Possibly L-arginine given to uremic rats enhances
iNOS activity in the kidney, which is totally dependent on
substrate availability [1, 2].
We found that unlike in the kidney, in the systemic circulation
of RMR rats the synthesis of NO increased, as reflected by higher
than normal plasma N027N03 concentrations. In addition,
NADPH-diaphorase documented an appreciable increase of NOS
activity in the aorta of uremic animals, suggesting that enhanced
systemic NO in RMR rats derives at least in part from higher than
normal synthetic activity in large vessels. Increased diaphorase
staining paralleled the immunohistochemistry finding of higher
ecNOS and iNOS expression in the aorta of RMR rats.
The enhanced ecNOS expression and larger amount of NO
formed in large vessels of RMR rats can serve as a defense
mechanism to limit systemic blood pressure elevation in this
model. This possibility is supported by a recent study showing that
L-NAME treatment aggravate arterial hypertension in rats with
RMR [62]. A similar system may operate even in non-uremic
models of hypertension [63], as documented by findings that NO
synthesis (measured by conversion of radiolabeled L-arginine to
L-citrulline) in aortic segments from spontaneously hypertensive
rats is twice that in aorta from normotensive controls [64].
Causes of high vascular ecNOS expression in RMR, as in other
experimental models of hypertension, very likely include changes
in shear stress since endothelial cells appear to release NO in
response to changes in blood flow [65], and ecNOS mRNA and
the corresponding protein are induced in endothelial cells after
exposure to fluid shear in a cone-and-plate apparatus [66]. A
similar mechanism operates in hypertension where pulsatile
stretch and distension of the arterial wall favor NO release, as
indicated by recent findings that cyclic strain induces the expres-
sion of ecNOS transcripts and protein levels in cultured endothe-
hal cells [67].
Besides ecNOS, in this study we found an increased expression
of iNOS in systemic vessels of RMR rats that was not confined to
the endothelium but was also detectable in smooth muscle. These
results are consistent with a previous study showing that plasma
from uremic humans stimulated NO synthesis (conceivably by
induction of iNOS activity) more than normal plasma [25]. The
stimulatory activity of uremic plasma was attributed to TNFo, a
potent inducer of iNOS [29], that circulates in increased amounts
in the plasma of patients with chronic renal failure either undia-
lyzed [68] or on maintenance hemodialysis, [25, 68]. Both in
uremic animals [69] and humans [70] plasma cGMP is consider-
ably higher than normal and there is evidence that cGMP
stimulates NO formation through induction of iNOS mRNA [71].
The stimulatory activity is associated with enhanced TNFx
mRNA expression and can be substantially prevented by antibod-
ies that neutralize TNFa [71]. It is therefore possible that
excessive formation of cGMP in uremia is responsible for iNOS
induction in systemic vessels, an effect that appears to be medi-
ated by TNFa.
Besides its vasoactive properties, NO inhibits platelet aggrega-
tion in vitro [1, 2] and platelet adhesion to cultured endothelial
cells [1, 2]. The in viva counterpart of this activity is the prolon-
gation of skin bleeding time observed in healthy volunteers given
NO by inhalation [72]. Since uremic animals and humans do have
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Fig. 7. Localization of NOS isoforms in the thoracic aortas. Sections from CTR and RMR rats studied 90 days after surgery are presented in panels
A, C, E and panels B, D, F, respectively. A and B. Histochemical staining for NOS enzymatic activity by the NADPH-diaphorase method. C and D.
Immunoperoxidase with a specific antibody against ecNOS. E and F. Immunoperoxidase with a specific antibody against iNOS. NOS activity as well as
ecNOS and iNOS staining are markedly increased on arterial endothelium in the RMR aortas. In RMR aortas vascular smooth muscle cell iNOS signal
is focally increased too. No staining is seen when primary antibodies are omitted (panel G, ecNOS; panel H, iNOS; magnification x535; bar = 20 sm).
Publication of this figure in color was made possible by a grant from Hoechst Marion Roussel, Frankfurt am Main, Germany.
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a prolonged bleeding time [22, 23] that is normalized in animals by
the NO antagonist L-NMMA [24], it seems logical to postulate
that excessive systemic NO formation may play a role in the
abnormal primary hemostasis of uremia.
In summary, in the present paper we present an integrated view
of the potential role of the L-arginine-NO pathway in the
physiology and pathology of the uremic condition.
In the kidney, with the progressive development of renal
insufficiency, less and less NO is formed locally, apparently as a
consequence of a time-dependent progressive reduction in the
amount of the iNOS molecule expressed in the kidney. In this
setting a marked reduction of NO, in the face of continuous local
generation of vasoconstrictor and promitogenic substances, may
well contribute to intraglomerular capillary hypertension and cell
proliferation.
By contrast, uremia appears to involve an abnormally large
amount of NO being released into the systemic circulation, and
our present study indicates consistently that this is a consequence
of excessive generation of the gas by systemic vessels due to
upregulation of both ecNOS and iNOS. While the increase in
vascular ecNOS occurs early in response to progressive renal
function deterioration, up-regulation of iNOS can only be de-
tected in the advanced phases of the disease and is not confined to
the smooth muscle cells, but also involves the vascular endothe-
hum. We suggest that up-regulation of NO-forming enzymes
might be an early defense mechanism against hypertension of
uremia. On the other hand, more NO available to circulating cells
may sustain the bleeding tendency, a well-known complication of
uremia in experimental animals [22] and humans [23].
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